Strategies toward single-donor islets of Langerhans transplantation

Current Opinion in Organ Transplantation

Volumn 16, Issue 6, 2011, Pages 627-631

  Shapiro, A M James ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Langerhans transplantation; single donor islets; type 1 diabetes

Indexed keywords

APOPTOSIS; CELL CULTURE; CELL ISOLATION; DONOR SELECTION; ENGRAFTMENT; GROWTH STIMULATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; METABOLISM; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; REVIEW; THROMBOSIS;

ANIMALS; DIABETES MELLITUS, TYPE 1; DONOR SELECTION; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISLETS OF LANGERHANS TRANSPLANTATION; TISSUE DONORS; TREATMENT OUTCOME;

EID: 81255142633     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32834cfb84     Document Type: Review

References (27)

1. Shapiro AMJ, Lakey JRT, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343:230-238. (Pubitemid 30490390)
2. Saidi F, Bradley J, Greer D, et al. Changing pattern of organ donation at a single center: are potential brain dead donors being lost to donation after cardiac death? Am J Transplant 2010; 10:2390-2391.
3. Matsumoto S, Okitsu T, Iwanaga Y, et al. Insulin independence after living donor distal pancreatectomy and islet allotransplantation. Lancet 2005; 365:1642-1644. (Pubitemid 40693414)
4. Ricordi C, Lacy PE, Finke EH, et al. Automated method for isolation of human pancreatic islets. Diabetes 1988; 37:413-420. (Pubitemid 18096377)
5. Papas KK, Colton CK, Nelson RA, et al. Human islet oxygen consumption rate and DNA measurements predict diabetes reversal in nude mice. Am J Transplant 2007; 7:707-713. (Pubitemid 46376439)
6. Papas KK, Avgoustiniatos ES, Tempelman LA, et al. High-density culture of human islets on top of silicone rubber membranes. Transplant Proc 2005; 37:3412-3414. (Pubitemid 41659903)
7. Hering BJ, Kandaswamy R, Ansite JD, et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA 2005; 293:830-835. (Pubitemid 40250366)
8. Hering BJ. Repurification: rescue rather than routine remedy. Am J Transplant 2005; 5:1-2. (Pubitemid 40095120)
9. Koh A, Senior P, Salam A, et al. Insulin-heparin infusions peritransplant substantially improve single-donor clinical islet transplant success. Transplantation 2010; 89:465-471.
10. Johansson H, Lukinius A, Moberg L, et al. Tissue factor produced by the endocrine cells of the islets of Langerhans is associated with a negative outcome of clinical islet transplantation. Diabetes 2005; 54:1755.
11. Xenos ES, Farney AC, Widner MB, et al. Effect of tumor necrosis factor alpha and of the soluble tumor necrosis factor receptor on insulin secretion of isolated islets of Langerhans. Transplant Proc 1992; 24:2863-2864. (Pubitemid 23011733)
12. Shapiro AM, Ricordi C. Unraveling the secrets of single donor success in islet transplantation. Am J Transplant 2004; 4:295-298. (Pubitemid 38282283)
13. Matsumoto S, Takita M, Chaussabel D, et al. Improving efficacy of clinical islet transplantation with Iodixanol based islet purification, thymoglobulin induction and blockage of IL-1-beta and TNF-alpha. Cell Transplant 2011. doi: 10.3723/096368910X564058
14. Emamaullee J, Rajotte RV, Liston P, et al. XIAP overexpression in human islets prevents early posttransplant apoptosis and reduces the islet mass needed to treat diabetes. Diabetes 2005; 54:2541-2548. (Pubitemid 41233574)
15. McCall M, Toso C, Emamaullee J, et al. The caspase inhibitor IDN-6556 (PF3491390) improves marginal mass engraftment after islet transplantation in mice. Surgery 2011; 150:48-55.
16. Cabric S, Eich T, Sanchez J, et al. A new method for incorporating functional heparin onto the surface of islets of Langerhans. Tissue Eng Part C Methods 2008; 14:141-147. (Pubitemid 351838707)
17. Schmidt P, Magnusson C, Lundrgren T, et al. Low molecular weight dextran sulfate is well tolerated in humans and increases endogenous expression of islet protective hepatocyte growth factor. Transplantation 2008; 86:1523-1530.
18. Cechin SR, Perez-Alvarez I, Fenjves E, et al. Anti-inflammatory properties of exenatide in human pancreatic islets. Cell Transplant. 2011 doi: 10.3727/ 09638911X576027. [Epub ahead of print].
19. Faradji RN, Froud T, Messinger S, et al. Long-term metabolic and hormonal effects of exenatide on islet transplant recipients with allograft dysfunction. Cell Transplant 2009; 18:1247-1259.
20. Ghofaili KA, Fug M, Ao Z, et al. Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes. Transplantation 2007; 83:24-28. (Pubitemid 46104966)
21. Gangemi A, Salehi P, Hatipoglu B, et al. Islet transplantation for brittle type 1 diabetes: the UIC protocol. Am J Transplant 2008; 8:1250-1261. (Pubitemid 351763686)
22. Merani S, Truong W, Emamaullee JA, et al. Liraglutide, a long-acting human glucagon-like-peptide 1 analogue, improves glucose hemostasis in marginal mass islet transplantation in mice. Endocrinology 2008; 149:4322-4328.
23. Emamaullee JA, Merani S, Toso C, et al. Porcine marginal mass islet autografts resist metabolic failure over time and are enhanced by early treatment with Liraglutide. Endocrinology 2009; 150:2145-2152.
24. Toso C, McCall M, Emamaullee J, et al. Liraglutide, a long-acting human glucagon-like peptide 1 analogue, improves human islet survival in culture. Transpl Int 2010; 23:259-265.
25. Suarez-Pinzon WL, Lakey JR, Rabinovitch A. Combination therapy with glucagon-like peptide-1 and gastrin induces beta-cell neogenesis from pancreatic duct cells in human islets transplanted in immunodeficient diabetic mice. Cell Transplant 2008; 17:631-640.
26. Nir T, Melton DA, Dor Y. Recovery from diabetes in mice by beta cell regeneration. J Clin Invest 2007; 117:2553-2561. (Pubitemid 47494356)
27. Posselt AM, Szot GL, Frassetto LA, et al. Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade. Transplantation 2010; 90:1595-1601.